ORIC-533 for Multiple Myeloma

Phase-Based Progress Estimates
Icahn School of Medicine at Mount Sinai, New York, NYMultiple MyelomaORIC-533 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug for patients with multiple myeloma who have run out of other treatment options. They will establish a safe dose and look at how the drug works in the body.

Eligible Conditions
  • Relapsed or Refractory Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

3 Primary · 3 Secondary · Reporting Duration: 36 months

12 months
Recommended Phase 2 Dose (RP2D)
28 Days
Area under the curve last concentration (AUClast)
Elimination half-life (t1/2)
Maximum plasma concentration (Cmax)
36 months
Number of participants with abnormal laboratory
Number of participants with adverse events

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

2 Treatment Groups

Dose Escalation
1 of 2
Dose Expansion
1 of 2

Experimental Treatment

48 Total Participants · 2 Treatment Groups

Primary Treatment: ORIC-533 · No Placebo Group · Phase 1

Dose Escalation
Experimental Group · 1 Intervention: ORIC-533 · Intervention Types: Drug
Dose Expansion
Experimental Group · 1 Intervention: ORIC-533 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 36 months

Who is running the clinical trial?

ORIC PharmaceuticalsLead Sponsor
6 Previous Clinical Trials
404 Total Patients Enrolled
Pratik S. Multani, MDStudy DirectorORIC Pharmaceuticals
3 Previous Clinical Trials
306 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are the researchers currently recruiting participants for this research project?

"Affirmative. Clinicaltrials.gov records indicate that this clinical trial, which was first posted on June 1st 2022 is currently in the process of patient recruitment. The research team needs to recruit 48 volunteers across 2 sites for further study participation." - Anonymous Online Contributor

Unverified Answer

How many participants will this clinical trial involve?

"Affirmative. Clinicaltrials.gov data reveals that this trial, posted on January 6th 2022 and last updated February 2nd 2022, is actively recruiting candidates. The study requires 48 patients from two distinct sites to participate." - Anonymous Online Contributor

Unverified Answer

What are the attendant risks of utilizing ORIC-533 to treat patients?

"Due to the early stage of clinical trials, ORIC-533's safety has been provisionally assessed as a 1. This is reflective of limited data that supports its efficacy and protection from harm." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.